• Decrease
  • Normal
  • Increase
U.S. Department of Health and Human Services

About FDA

Number of biosimilar biological product development (BPD) Type 1-4 meeting requests received in the month

Dictionary: Biosimilar biological product development (BPD) meeting refers to any meeting, other than a biosimilar initial advisory meeting, regarding the content of a development program, including a proposed design for, or data from, a study intended to support a biosimilar biological product application.

Information is current as of September 30, 2014.

Fiscal Year - 2014

Skip graphic and jump to text data

TimeTargetNumber
Oct 2013N/A0
Nov 2013N/A5
Dec 2013N/A6
Jan 2014N/A1
Feb 2014N/A6
Mar 2014N/A4
Apr 2014N/A3
May 2014N/A1
Jun 2014N/A2
Jul 2014N/A1
Aug 2014N/A9
Sep 2014N/A4

FY 2014 Total: 42

Footnotes

  • CDER began collecting data for the these measures in January 2013.

Number of biosimilar biological product development (BPD) Type 1-4 meetings held in the month

Fiscal Year - 2014
Skip graphic and jump to text data.

TimeTargetNumber
Oct 2013N/A2
Nov 2013N/A4
Dec 2013N/A3
Jan 2014N/A2
Feb 2014N/A2
Mar 2014N/A2
Apr 2014N/A4
May 2014N/A5
Jun 2014N/A2
Jul 2014N/A4
Aug 2014N/A2
Sep 2014N/A1

FY 2014 Total: 33

Glossary

Note: The data provided on this website is produced on an ongoing basis for performance management purposes and is subject to change due to updates of preliminary estimates, corrections, or other reasons. In addition, FDA may change the type or amount of data provided on this website at any time. Information marked as "Completed" may include measures and/or key projects for which activities are ongoing but no longer tracked as part of FDA-TRACK.